One week/three deals for Santaris’ RNA-targeting technology
By Nuala Moran
Friday, January 10, 2014
LONDON – It’s been a busy first week on the job for the new CEO of Santaris Pharma A/S, Donald deBethizy, as a trio of deals was announced, with Roche AG, Glaxosmithkline plc and Isarna Therapeutics GmbH, around the company’s RNA-targeting technology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.